

ASX ANNOUNCEMENT

19 October 2009

Cytopia opens fourth clinical centre for CYT997 glioma study

Cytopia Limited (ASX: CYT) has received ethics committee approval to commence dosing patients in its CYT997 Phase II clinical trial in glioblastoma multiforme (GBM) at the Gold Coast Hospital in Southport, Queensland.

The Gold Coast Hospital will be the company's fourth clinical site for this study. Dr Andrew Hill will act as local Principal Investigator.

GBM is an aggressive form of brain tumour which is currently treated by surgical resection, and/or radiation and chemotherapy. Despite these treatments, the condition recurs in most patients, leading to poor patient outcomes. GBM tumours are highly vascular, rendering them potentially susceptible to destruction by an anti-vascular agent such as CYT997.

The company will also shortly file the requisite regulatory submissions to the Medicines and Healthcare Products Regulatory Agency (MHRA) to enable dosing at clinical centres in the United Kingdom and is considering further centres in North America.

"The addition of the Gold Coast Hospital strengthens this program," said Mr Andrew Macdonald, CEO of Cytopia. "The company is looking forward to concluding the dose-escalation portion of this study early next year."

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent for the treatment of various cancers, and currently being trialled in Phase II clinical studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter a Phase I/II clinical study in 2009.

On 6 October 2009, Cytopia announced a proposed merger with Toronto, Canada based YM BioSciences Inc. Details can be found at www.cytopia.com.au. It is expected that a Scheme Booklet, further explaining the basis for the merger, will be provided to Cytopia shareholders in November 2009.

For more information please contact:

Mr Andrew Macdonald
Chief Executive Officer
T: +61 3 9208 4232
E: andrew.macdonald@cytopia.com.au

Dr Gregg Smith
Director, Drug Development
T: +61 3 9208 4234
E: gregg.smith@cytopia.com.au

or, visit our website at: www.cytopia.com.au